What happened with ENOV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Enovis Corporation makes devices that help patients manage musculoskeletal conditions without surgery or replace and reconstruct damaged joints and limbs. Its Prevention & Recovery business sells products such as orthopedic braces, bone-growth stimulators and physical therapy equipment. Reconstructive supplies implants and surgical instruments for joint replacement and limb reconstruction. The two businesses contribute roughly equal shares of sales.
Enovis sells through distributors and its own salespeople to hospitals, healthcare professionals and consumers. Some products are used by patients at home. It also submits claims on patients’ behalf and receives payments directly from Medicare, Medicaid and private insurers.
Sales depend heavily on healthcare professionals prescribing or recommending its products and on insurers covering the devices or related procedures adequately. Enovis cannot promote devices for uses the FDA has not cleared or approved. Continued marketing in the European Union and United Kingdom also depends on obtaining required device certifications before existing certificates expire.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Enovis also relies heavily on demand and reimbursement for bracing and rehabilitation, where important rivals Össur and Breg are missing from this list.
Zimmer Biomet competes with Enovis for orthopedic surgeons’ and hospitals’ purchases of joint implants and surgical technologies, so joint replacement demand matters to both. Its implant sales and new robotic technologies are worth watching for changes in the choices available to Enovis’s customers.
Stryker competes with Enovis in products used for joint replacement and limb reconstruction, exposing both to demand for those operations. Watch Stryker’s Orthopaedics sales rather than its overall results: that business accounted for 38% of its net sales in 2025.
Smith & Nephew competes with Enovis for surgeons choosing products for shoulder replacement and limb reconstruction. Its news about products for these procedures is more relevant to Enovis than its broad medical-technology sales.
Orthofix Medical competes with Enovis in devices that stimulate bone healing and products that stabilize limbs during reconstruction, with demand and reimbursement affecting both. Its bone growth therapy sales and limb reconstruction results offer a closer comparison than its overall sales.
Bioventus competes with Enovis in therapies that support recovery, including bone healing, so fracture-care demand and reimbursement matter to both. Watch its Restorative Therapies business for the overlap, rather than treating its pain treatments and surgical products as equally relevant.
Shoulder Innovations competes directly with Enovis for surgeons’ choice of shoulder replacement implants. Because it focuses exclusively on shoulder surgical care, its implant sales and news about surgical planning tools offer a focused view of competition for Enovis’s shoulder business.
Treace Medical Concepts and Enovis compete to sell bunion surgery systems and implants to foot and ankle surgeons. Watch adoption of Treace’s Lapiplasty system, which combines instruments and implants to correct bunions, for competition facing Enovis’s foot and ankle products.
Johnson & Johnson competes with Enovis through DePuy Synthes, which sells reconstructive orthopedic implants, but its parent also sells prescription medicines. DePuy Synthes implant news is therefore a more direct guide to Enovis’s competition than Johnson & Johnson’s overall results.
CONMED and Enovis compete in orthopedic surgical products, including offerings for surgeons correcting bunions. CONMED’s orthopedic sales are the more relevant comparison for Enovis: they represented 42% of net sales in 2025, with general surgery accounting for the rest.
Fed Interest Rate Decision
Enovis’s rate-sensitive borrowing can cost more or less as the Fed changes its policy rate, affecting the interest expense it pays and cash left for its medical-device business.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets a higher rate than expected, Enovis may pay more interest on debt that reprices, leaving less cash for operations, investment in surgical instruments and other business needs.
If it comes in below expectations
If the Fed sets a lower rate than expected, interest costs on debt that reprices may ease, leaving Enovis more cash for operations, investment in surgical instruments and other business needs.
Stryker Corporation earningsSYK
Stryker's Orthopaedics sales and procedure trends show whether the joint-replacement and limb-reconstruction market Enovis also serves is growing or getting more competitive.
Read Stryker's Orthopaedics sales alongside its explanation of procedure trends. Sales rising with joint-replacement and limb-reconstruction procedures would point to demand supporting the market both companies serve. Falling sales, or growth driven mainly by Stryker winning share, would mean Enovis's Reconstructive business faces weaker demand or tougher competition. Stryker's growth alone does not establish that Enovis is growing.
Orthofix Medical Inc. earningsOFIX
Orthofix Medical's bone-growth therapy sales and limb-reconstruction results show demand and competition in products that overlap with Enovis's bone-growth stimulators and related devices.
Read Orthofix Medical's bone-growth therapy sales alongside its limb-reconstruction results, and note what it says about reimbursement. Strength in both, without worsening reimbursement, would point to supportive demand for Enovis's overlapping bone-healing and limb-stabilization products. Weakness, especially alongside tighter reimbursement, would flag possible demand or payment pressure for Enovis too, though a competitor's results cannot establish Enovis's own sales trend.
Enovis Corporation earningsThis company
Enovis's report will show whether implants and surgical tools are growing its Reconstructive business without Prevention & Recovery falling behind.
Read net sales and adjusted EBITDA for both segments together; adjusted EBITDA is the company's adjusted measure of earnings before interest, taxes, depreciation and amortization. Reconstructive sales and adjusted EBITDA rising while Prevention & Recovery holds steady would show growth in implants and surgical tools without weakness in the other business. If Reconstructive stalls or falls and P&R alone keeps total sales up, growth in the higher-margin business remains fragile.
Shoulder Innovations, Inc. earningsSI
Shoulder Innovations' implant sales and use of surgical-planning tools show whether it is winning surgeons' choices in the shoulder market Enovis also serves.
Read shoulder-implant sales together with adoption of surgical-planning tools. Strength in both would suggest Shoulder Innovations is winning more surgeons' choices, sharpening competition for Enovis's shoulder business. If both are weak, there is less evidence of competitive gains, but that alone would not show that overall shoulder-replacement demand is falling.
Treace Medical Concepts, Inc. earningsTMCI
Treace Medical Concepts' Lapiplasty sales and adoption show whether it is winning surgeon choices in bunion surgery, where Enovis's foot-and-ankle products also compete.
Read Treace Medical Concepts' Lapiplasty sales alongside adoption of the system. Sales growth with rising adoption would show surgeons choosing its bunion-correction system more often, intensifying competition for Enovis's foot-and-ankle products. If both are weak, there is less evidence that Treace is winning surgeon choices, but that does not prove Enovis is selling more.
